Geron Corp
GERN Real Time Price USDRecent trades of GERN by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Ro Khanna House / D | Purchase $15,001 - $50,000 | N/A |
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in GERN holdings by institutional investors
Quarterly net insider trading by GERN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$60,000 Jul 20, 2026 Issue: Energy/Nuclear
-
$30,000 Apr 20, 2026 Issue: Medicare/Medicaid
-
$60,000 Apr 14, 2026 Issue: Energy/Nuclear
-
$60,000 Jan 14, 2026 Issue: Energy/Nuclear
-
$60,000 Oct 23, 2025 Issue: Energy/Nuclear
-
$30,000 Oct 20, 2025 Issue: Medicare/Medicaid
-
$60,000 Jul 21, 2025 Issue: Energy/Nuclear
-
$30,000 Jul 20, 2025 Issue: Medicare/Medicaid
-
$30,000 Apr 19, 2025 Issue: Medicare/Medicaid
-
$20,000 Apr 14, 2025 Issue: Energy/Nuclear
-
$30,000 Jan 20, 2025 Issue: Health Issues
-
$20,000 Oct 21, 2024 Issue: Health Issues
-
$30,000 Jul 21, 2024 Issue: Health Issues
-
$30,000 Jan 22, 2024 Issue: Health Issues
-
$10,000 Oct 19, 2023 Issue: Health Issues
Former government officials who have lobbied for GERN
GERN Estimated quarterly lobbying spending
GERN Revenue by Segment or Geography
New GERN patent grants
-
Patent Title: Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors Apr. 24, 2018
-
Patent Title: Rna amidates and thioamidates for rnai Nov. 21, 2017
-
Patent Title: Oligonucleotide compositions and methods of making the same Oct. 24, 2017
-
Patent Title: C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders Sep. 26, 2017
-
Patent Title: 2′-arabino-fluorooligonucleotide n3′→p5′ phosphoramidates: their synthesis and use Sep. 19, 2017
-
Patent Title: Compounds having anti-adhesive effects on cancer cells Aug. 15, 2017
-
Patent Title: Phosphorodiamidate backbone linkage for oligonucleotides Jul. 18, 2017
-
Patent Title: Modified oligonucleotides for telomerase inhibition May. 23, 2017
-
Patent Title: Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr Apr. 18, 2017
-
Patent Title: Method for identification of sensitivity of a patient to telomerase inhibition therapy Apr. 11, 2017
-
Patent Title: Guanine analogs as telomerase substrates and telomere length affectors Mar. 14, 2017
-
Patent Title: Oligonucleotide conjugates Feb. 21, 2017
-
Patent Title: Modified oligonucleotides for telomerase inhibition Aug. 02, 2016
-
Patent Title: Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms Jun. 28, 2016
-
Patent Title: Synthesis of protected 3′-amino nucleoside monomers Jun. 14, 2016
-
Patent Title: C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders Jan. 05, 2016
-
Patent Title: Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors Dec. 01, 2015
-
Patent Title: Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors Oct. 13, 2015
-
Patent Title: Rna amidates and thioamidates for rnai Sep. 15, 2015
-
Patent Title: Oligonucleotide conjugates Jul. 07, 2015
-
Patent Title: 2′-arabino-fluorooligonucleotide n3′→p5′ phosphoramidates: their synthesis and use Dec. 09, 2014
-
Patent Title: Method for identification of sensitivity of a patient to telomerase inhibition therapy Nov. 04, 2014
-
Patent Title: Nucleic acids encoding inactive variants of human telomerase Aug. 05, 2014
-
Patent Title: Compounds having anti-adhesive effects on cancer cells Jul. 22, 2014
-
Patent Title: Synthesis of protected 3′-amino nucleoside monomers Jun. 10, 2014
-
Patent Title: Method for eliciting an immune response to human telomerase reverse transcriptase Apr. 29, 2014
-
Patent Title: Synthetic surfaces for culturing stem cell derived cardiomyocytes Oct. 22, 2013
-
Patent Title: Protocols for making hepatocytes from embryonic stem cells Oct. 01, 2013
-
Patent Title: Compound screening using chondrocytes derived from primate pluripotent stem cells Oct. 01, 2013
-
Patent Title: Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells Aug. 20, 2013
-
Patent Title: Oligonucleotide conjugates May. 14, 2013
-
Patent Title: In vitro differentiated cell and human embryonic stem cell population Apr. 23, 2013
-
Patent Title: Differentiation and enrichment of islet-like cells from human pluripotent stem cells Apr. 09, 2013
-
Patent Title: 2′-arabino-fluorooligonucleotide n3′→p5′ phosphoramidates: their synthesis and use Feb. 19, 2013
-
Patent Title: Synthetic surfaces for culturing cells in chemically defined media Jan. 15, 2013
-
Patent Title: Swellable (meth)acrylate surfaces for culturing cells in chemically defined media Dec. 11, 2012
-
Patent Title: Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes Dec. 04, 2012
-
Patent Title: Neural cell populations from primate pluripotent stem cells Aug. 28, 2012
-
Patent Title: Neural progenitor cell populations Aug. 28, 2012
-
Patent Title: Synthetic surfaces for culturing stem cell derived cardiomyocytes Aug. 14, 2012
-
Patent Title: Human telomerase catalytic subunit Aug. 07, 2012
-
Patent Title: Kit for detection of telomerase reverse transcriptase nucleic acids Jul. 17, 2012
-
Patent Title: Cns-tumor treatment method and composition Apr. 10, 2012
-
Patent Title: Use of tgf beta superfamily antagonists and neurotrophins to make neurons from embryonic stem cells Apr. 10, 2012
-
Patent Title: Differentiation of primate pluripotent cells to hepatocyte-lineage cells Apr. 03, 2012
-
Patent Title: Neural progenitor cell populations Apr. 03, 2012
-
Patent Title: Micro-carrier culture system for rapid expansion of human embryonic stem cells Jan. 17, 2012
-
Patent Title: Differentiation of primate pluripotent stem cells to hematopoietic lineage cells Jan. 10, 2012
-
Patent Title: Cancer treatment by combined inhibition of proteasome and telomerase activities Aug. 16, 2011
-
Patent Title: 2′-arabino-fluorooligonucleotide n3′-p5′ phosphoramidates: their synthesis and use Aug. 02, 2011
Federal grants, loans, and purchases
Estimated quarterly amount awarded to GERN from public contracts
Recent insights relating to GERN
Recent picks made for GERN stock on CNBC
ETFs with the largest estimated holdings in GERN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $GERN stock a Buy, Sell, or Hold?
- What is the price target for $GERN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $GERN stock?
- Who owns the most shares of $GERN stock?
- What funds own $GERN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view GERN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
- Address Foster City, CA
- Market Cap 809.5 million
- Employees 258
- Industrial Classification Pharmaceutical Preparations
Geron Corp (GERN) Historical Stock Prices
Geron Corp (GERN) closed at $1.26 on September 25, 2026. Over the past year its adjusted close ranged from $1.07 to $1.95. Daily prices go back to January 2, 2014, 3,201 trading days in all.
- 1 month-17.65%
- 3 months-4.55%
- Year to date-4.55%
- 1 year-0.79%
- 3 years-41.67%
- 5 years-8.03%
- Max-74.29%
Quiver Premium charts GERN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | 1.26 | 1.27 | 1.24 | 1.26 | 1.26 | 10,302,825 |
| Sep 24, 2026 | 1.23 | 1.27 | 1.20 | 1.26 | 1.26 | 6,413,404 |
| Sep 23, 2026 | 1.33 | 1.33 | 1.22 | 1.24 | 1.24 | 10,925,293 |
| Sep 22, 2026 | 1.32 | 1.32 | 1.29 | 1.31 | 1.31 | 6,215,161 |
| Sep 21, 2026 | 1.30 | 1.31 | 1.28 | 1.30 | 1.30 | 5,897,021 |
| Sep 18, 2026 | 1.32 | 1.33 | 1.29 | 1.30 | 1.30 | 17,244,691 |
| Sep 17, 2026 | 1.32 | 1.34 | 1.30 | 1.32 | 1.32 | 9,819,461 |
| Sep 16, 2026 | 1.32 | 1.33 | 1.27 | 1.29 | 1.29 | 11,439,985 |
| Sep 15, 2026 | 1.37 | 1.37 | 1.30 | 1.31 | 1.31 | 16,486,722 |
| Sep 14, 2026 | 1.36 | 1.40 | 1.34 | 1.37 | 1.37 | 12,124,515 |
| Sep 11, 2026 | 1.39 | 1.41 | 1.34 | 1.35 | 1.35 | 9,867,666 |
| Sep 10, 2026 | 1.39 | 1.41 | 1.36 | 1.37 | 1.37 | 7,694,587 |
| Sep 9, 2026 | 1.50 | 1.51 | 1.40 | 1.40 | 1.40 | 9,244,762 |
| Sep 8, 2026 | 1.55 | 1.58 | 1.50 | 1.51 | 1.51 | 8,306,118 |
| Sep 4, 2026 | 1.49 | 1.59 | 1.46 | 1.57 | 1.57 | 11,478,945 |
| Sep 3, 2026 | 1.58 | 1.60 | 1.48 | 1.51 | 1.51 | 14,234,297 |
| Sep 2, 2026 | 1.49 | 1.62 | 1.48 | 1.59 | 1.59 | 26,890,023 |
| Sep 1, 2026 | 1.47 | 1.50 | 1.46 | 1.48 | 1.48 | 7,886,442 |
| Aug 31, 2026 | 1.50 | 1.51 | 1.45 | 1.49 | 1.49 | 7,247,301 |
| Aug 28, 2026 | 1.53 | 1.53 | 1.49 | 1.51 | 1.51 | 7,416,982 |
| Aug 27, 2026 | 1.54 | 1.56 | 1.50 | 1.53 | 1.53 | 7,883,188 |
| Aug 26, 2026 | 1.58 | 1.58 | 1.50 | 1.53 | 1.53 | 9,123,636 |
| Aug 25, 2026 | 1.55 | 1.59 | 1.50 | 1.55 | 1.55 | 9,843,888 |
| Aug 24, 2026 | 1.53 | 1.55 | 1.44 | 1.52 | 1.52 | 13,109,416 |
| Aug 21, 2026 | 1.56 | 1.57 | 1.50 | 1.52 | 1.52 | 4,433,504 |
| Aug 20, 2026 | 1.58 | 1.59 | 1.54 | 1.55 | 1.55 | 5,987,863 |
| Aug 19, 2026 | 1.57 | 1.59 | 1.52 | 1.59 | 1.59 | 8,015,954 |
| Aug 18, 2026 | 1.52 | 1.56 | 1.51 | 1.53 | 1.53 | 4,242,479 |
| Aug 17, 2026 | 1.46 | 1.55 | 1.45 | 1.53 | 1.53 | 8,412,319 |
| Aug 14, 2026 | 1.53 | 1.53 | 1.44 | 1.47 | 1.47 | 11,157,986 |
| Aug 13, 2026 | 1.58 | 1.60 | 1.52 | 1.53 | 1.53 | 5,633,568 |
| Aug 12, 2026 | 1.63 | 1.64 | 1.56 | 1.57 | 1.57 | 10,202,342 |
| Aug 11, 2026 | 1.50 | 1.65 | 1.47 | 1.63 | 1.63 | 12,716,754 |
| Aug 10, 2026 | 1.45 | 1.51 | 1.43 | 1.48 | 1.48 | 5,641,719 |
| Aug 7, 2026 | 1.56 | 1.60 | 1.46 | 1.48 | 1.48 | 8,885,551 |
| Aug 6, 2026 | 1.60 | 1.62 | 1.53 | 1.57 | 1.57 | 16,207,172 |
| Aug 5, 2026 | 1.37 | 1.63 | 1.36 | 1.63 | 1.63 | 36,080,015 |
| Aug 4, 2026 | 1.32 | 1.36 | 1.31 | 1.34 | 1.34 | 13,464,407 |
| Aug 3, 2026 | 1.30 | 1.30 | 1.24 | 1.28 | 1.28 | 19,560,705 |
| Jul 31, 2026 | 1.35 | 1.37 | 1.22 | 1.29 | 1.29 | 19,611,828 |
| Jul 30, 2026 | 1.42 | 1.43 | 1.33 | 1.34 | 1.34 | 19,466,252 |
| Jul 29, 2026 | 1.44 | 1.46 | 1.40 | 1.40 | 1.40 | 5,656,182 |
| Jul 28, 2026 | 1.48 | 1.53 | 1.41 | 1.45 | 1.45 | 5,043,308 |
| Jul 27, 2026 | 1.45 | 1.53 | 1.45 | 1.48 | 1.48 | 8,915,738 |
| Jul 24, 2026 | 1.45 | 1.46 | 1.41 | 1.42 | 1.42 | 3,292,732 |
| Jul 23, 2026 | 1.41 | 1.46 | 1.39 | 1.45 | 1.45 | 4,264,753 |
| Jul 22, 2026 | 1.44 | 1.45 | 1.40 | 1.41 | 1.41 | 5,693,370 |
| Jul 21, 2026 | 1.43 | 1.48 | 1.42 | 1.44 | 1.44 | 5,143,963 |
| Jul 20, 2026 | 1.44 | 1.48 | 1.41 | 1.44 | 1.44 | 5,209,660 |
| Jul 17, 2026 | 1.41 | 1.49 | 1.40 | 1.44 | 1.44 | 4,784,000 |
| Jul 16, 2026 | 1.41 | 1.45 | 1.40 | 1.42 | 1.42 | 6,800,693 |
| Jul 15, 2026 | 1.37 | 1.45 | 1.36 | 1.42 | 1.42 | 6,178,427 |
| Jul 14, 2026 | 1.42 | 1.43 | 1.35 | 1.38 | 1.38 | 11,736,079 |
| Jul 13, 2026 | 1.49 | 1.51 | 1.41 | 1.42 | 1.42 | 7,162,331 |
| Jul 10, 2026 | 1.56 | 1.57 | 1.47 | 1.50 | 1.50 | 10,348,929 |
| Jul 9, 2026 | 1.56 | 1.62 | 1.55 | 1.56 | 1.56 | 11,741,658 |
| Jul 8, 2026 | 1.47 | 1.56 | 1.46 | 1.56 | 1.56 | 13,532,895 |
| Jul 7, 2026 | 1.44 | 1.50 | 1.41 | 1.49 | 1.49 | 11,479,010 |
| Jul 6, 2026 | 1.36 | 1.46 | 1.35 | 1.44 | 1.44 | 11,315,316 |
| Jul 2, 2026 | 1.29 | 1.36 | 1.27 | 1.36 | 1.36 | 10,548,071 |
| Jul 1, 2026 | 1.28 | 1.31 | 1.26 | 1.27 | 1.27 | 9,923,008 |
| Jun 30, 2026 | 1.32 | 1.32 | 1.26 | 1.28 | 1.28 | 12,592,432 |
| Jun 29, 2026 | 1.33 | 1.37 | 1.29 | 1.30 | 1.30 | 14,561,547 |
| Jun 26, 2026 | 1.37 | 1.41 | 1.28 | 1.32 | 1.32 | 36,634,117 |
| Jun 25, 2026 | 1.38 | 1.47 | 1.36 | 1.37 | 1.37 | 9,546,037 |
| Jun 24, 2026 | 1.36 | 1.45 | 1.35 | 1.39 | 1.39 | 19,234,596 |
| Jun 23, 2026 | 1.32 | 1.36 | 1.29 | 1.35 | 1.35 | 13,103,262 |
| Jun 22, 2026 | 1.28 | 1.37 | 1.27 | 1.34 | 1.34 | 18,713,541 |
| Jun 18, 2026 | 1.25 | 1.30 | 1.23 | 1.26 | 1.26 | 22,995,891 |
| Jun 17, 2026 | 1.18 | 1.28 | 1.17 | 1.23 | 1.23 | 13,869,369 |
| Jun 16, 2026 | 1.16 | 1.18 | 1.14 | 1.18 | 1.18 | 10,258,721 |
| Jun 15, 2026 | 1.16 | 1.21 | 1.15 | 1.15 | 1.15 | 9,845,350 |
| Jun 12, 2026 | 1.14 | 1.17 | 1.12 | 1.15 | 1.15 | 8,110,734 |
| Jun 11, 2026 | 1.10 | 1.22 | 1.08 | 1.14 | 1.14 | 31,746,036 |
| Jun 10, 2026 | 1.11 | 1.14 | 1.09 | 1.10 | 1.10 | 14,737,296 |
| Jun 9, 2026 | 1.14 | 1.17 | 1.11 | 1.12 | 1.12 | 13,609,303 |
| Jun 8, 2026 | 1.19 | 1.19 | 1.12 | 1.13 | 1.13 | 11,184,588 |
| Jun 5, 2026 | 1.21 | 1.21 | 1.16 | 1.17 | 1.17 | 9,600,839 |
| Jun 4, 2026 | 1.18 | 1.23 | 1.17 | 1.21 | 1.21 | 9,830,723 |
| Jun 3, 2026 | 1.18 | 1.19 | 1.14 | 1.16 | 1.16 | 10,092,775 |
| Jun 2, 2026 | 1.21 | 1.22 | 1.15 | 1.17 | 1.17 | 13,031,778 |
| Jun 1, 2026 | 1.25 | 1.26 | 1.20 | 1.21 | 1.21 | 8,361,141 |
| May 29, 2026 | 1.27 | 1.29 | 1.24 | 1.25 | 1.25 | 11,696,967 |
| May 28, 2026 | 1.27 | 1.28 | 1.25 | 1.25 | 1.25 | 10,148,304 |
| May 27, 2026 | 1.28 | 1.30 | 1.26 | 1.26 | 1.26 | 8,286,826 |
| May 26, 2026 | 1.30 | 1.32 | 1.28 | 1.28 | 1.28 | 10,873,595 |
| May 22, 2026 | 1.26 | 1.29 | 1.25 | 1.28 | 1.28 | 6,867,345 |
| May 21, 2026 | 1.25 | 1.28 | 1.22 | 1.26 | 1.26 | 8,149,887 |
| May 20, 2026 | 1.24 | 1.28 | 1.23 | 1.26 | 1.26 | 8,387,523 |
| May 19, 2026 | 1.23 | 1.25 | 1.20 | 1.22 | 1.22 | 10,555,434 |
| May 18, 2026 | 1.30 | 1.30 | 1.22 | 1.23 | 1.23 | 10,359,597 |
| May 15, 2026 | 1.40 | 1.40 | 1.28 | 1.29 | 1.29 | 16,158,372 |
| May 14, 2026 | 1.41 | 1.43 | 1.36 | 1.40 | 1.40 | 18,612,276 |
| May 13, 2026 | 1.40 | 1.45 | 1.40 | 1.41 | 1.41 | 25,244,730 |
| May 12, 2026 | 1.41 | 1.44 | 1.39 | 1.40 | 1.40 | 26,741,812 |
| May 11, 2026 | 1.39 | 1.46 | 1.38 | 1.39 | 1.39 | 32,391,608 |
| May 8, 2026 | 1.50 | 1.53 | 1.38 | 1.39 | 1.39 | 12,746,103 |
| May 7, 2026 | 1.56 | 1.58 | 1.42 | 1.46 | 1.46 | 17,376,688 |
| May 6, 2026 | 1.66 | 1.73 | 1.55 | 1.58 | 1.58 | 21,462,827 |
| May 5, 2026 | 1.60 | 1.66 | 1.57 | 1.65 | 1.65 | 15,760,554 |
| May 4, 2026 | 1.56 | 1.60 | 1.54 | 1.57 | 1.57 | 9,965,157 |
| May 1, 2026 | 1.55 | 1.60 | 1.52 | 1.58 | 1.58 | 9,101,912 |
| Apr 30, 2026 | 1.51 | 1.55 | 1.50 | 1.54 | 1.54 | 11,190,015 |
| Apr 29, 2026 | 1.50 | 1.52 | 1.48 | 1.51 | 1.51 | 12,001,441 |
| Apr 28, 2026 | 1.52 | 1.56 | 1.50 | 1.51 | 1.51 | 9,451,723 |
| Apr 27, 2026 | 1.50 | 1.59 | 1.50 | 1.53 | 1.53 | 12,325,288 |
| Apr 24, 2026 | 1.52 | 1.54 | 1.49 | 1.50 | 1.50 | 12,931,535 |
| Apr 23, 2026 | 1.54 | 1.57 | 1.50 | 1.50 | 1.50 | 8,988,733 |
| Apr 22, 2026 | 1.53 | 1.57 | 1.50 | 1.55 | 1.55 | 16,683,716 |
| Apr 21, 2026 | 1.55 | 1.56 | 1.47 | 1.50 | 1.50 | 15,757,209 |
| Apr 20, 2026 | 1.66 | 1.69 | 1.55 | 1.56 | 1.56 | 21,052,060 |
| Apr 17, 2026 | 1.72 | 1.74 | 1.66 | 1.68 | 1.68 | 23,705,606 |
| Apr 16, 2026 | 1.70 | 1.71 | 1.65 | 1.69 | 1.69 | 8,451,345 |
| Apr 15, 2026 | 1.77 | 1.77 | 1.68 | 1.69 | 1.69 | 21,002,983 |
| Apr 14, 2026 | 1.75 | 1.80 | 1.74 | 1.77 | 1.77 | 17,827,990 |
| Apr 13, 2026 | 1.66 | 1.76 | 1.65 | 1.73 | 1.73 | 23,450,019 |
| Apr 10, 2026 | 1.78 | 1.78 | 1.66 | 1.67 | 1.67 | 16,569,452 |
| Apr 9, 2026 | 1.71 | 1.77 | 1.68 | 1.76 | 1.76 | 17,943,764 |
| Apr 8, 2026 | 1.81 | 1.82 | 1.67 | 1.71 | 1.71 | 20,090,978 |
| Apr 7, 2026 | 1.74 | 1.84 | 1.72 | 1.74 | 1.74 | 17,091,711 |
| Apr 6, 2026 | 1.66 | 1.79 | 1.66 | 1.75 | 1.75 | 39,279,049 |
| Apr 2, 2026 | 1.61 | 1.69 | 1.59 | 1.66 | 1.66 | 33,581,583 |
| Apr 1, 2026 | 1.51 | 1.66 | 1.50 | 1.66 | 1.66 | 26,477,827 |
| Mar 31, 2026 | 1.43 | 1.50 | 1.43 | 1.49 | 1.49 | 14,404,601 |
| Mar 30, 2026 | 1.40 | 1.43 | 1.38 | 1.41 | 1.41 | 16,680,009 |
| Mar 27, 2026 | 1.51 | 1.54 | 1.40 | 1.40 | 1.40 | 19,254,006 |
| Mar 26, 2026 | 1.54 | 1.59 | 1.53 | 1.54 | 1.54 | 19,706,518 |
| Mar 25, 2026 | 1.55 | 1.59 | 1.52 | 1.57 | 1.57 | 14,540,203 |
| Mar 24, 2026 | 1.50 | 1.53 | 1.48 | 1.51 | 1.51 | 17,645,244 |
| Mar 23, 2026 | 1.50 | 1.61 | 1.47 | 1.54 | 1.54 | 19,754,109 |
| Mar 20, 2026 | 1.55 | 1.55 | 1.45 | 1.46 | 1.46 | 39,135,225 |
| Mar 19, 2026 | 1.53 | 1.56 | 1.44 | 1.55 | 1.55 | 22,187,158 |
| Mar 18, 2026 | 1.63 | 1.63 | 1.54 | 1.55 | 1.55 | 15,074,043 |
| Mar 17, 2026 | 1.68 | 1.70 | 1.61 | 1.62 | 1.62 | 10,937,759 |
| Mar 16, 2026 | 1.59 | 1.72 | 1.59 | 1.65 | 1.65 | 13,708,009 |
| Mar 13, 2026 | 1.62 | 1.63 | 1.57 | 1.58 | 1.58 | 13,663,998 |
| Mar 12, 2026 | 1.63 | 1.67 | 1.53 | 1.60 | 1.60 | 24,741,630 |
| Mar 11, 2026 | 1.61 | 1.72 | 1.58 | 1.66 | 1.66 | 20,746,870 |
| Mar 10, 2026 | 1.62 | 1.66 | 1.57 | 1.63 | 1.63 | 21,640,582 |
| Mar 9, 2026 | 1.50 | 1.63 | 1.50 | 1.62 | 1.62 | 13,291,106 |
| Mar 6, 2026 | 1.40 | 1.59 | 1.40 | 1.53 | 1.53 | 18,971,081 |
| Mar 5, 2026 | 1.46 | 1.48 | 1.41 | 1.42 | 1.42 | 17,966,564 |
| Mar 4, 2026 | 1.45 | 1.51 | 1.40 | 1.47 | 1.47 | 16,756,933 |
| Mar 3, 2026 | 1.51 | 1.54 | 1.42 | 1.44 | 1.44 | 21,445,979 |
| Mar 2, 2026 | 1.60 | 1.65 | 1.54 | 1.55 | 1.55 | 14,503,997 |
| Feb 27, 2026 | 1.63 | 1.75 | 1.61 | 1.68 | 1.68 | 11,297,209 |
| Feb 26, 2026 | 1.72 | 1.74 | 1.54 | 1.65 | 1.65 | 20,967,146 |
| Feb 25, 2026 | 1.68 | 1.84 | 1.56 | 1.72 | 1.72 | 30,286,235 |
| Feb 24, 2026 | 1.77 | 1.97 | 1.76 | 1.95 | 1.95 | 23,895,651 |
| Feb 23, 2026 | 1.84 | 1.90 | 1.72 | 1.77 | 1.77 | 25,897,801 |
| Feb 20, 2026 | 1.90 | 1.92 | 1.79 | 1.88 | 1.88 | 25,231,772 |
| Feb 19, 2026 | 1.94 | 2.01 | 1.84 | 1.92 | 1.92 | 25,145,361 |
| Feb 18, 2026 | 1.79 | 1.96 | 1.76 | 1.94 | 1.94 | 25,095,837 |
| Feb 17, 2026 | 1.65 | 1.85 | 1.65 | 1.80 | 1.80 | 20,567,733 |
| Feb 13, 2026 | 1.63 | 1.73 | 1.62 | 1.65 | 1.65 | 12,683,400 |
| Feb 12, 2026 | 1.64 | 1.65 | 1.55 | 1.63 | 1.63 | 9,919,700 |
| Feb 11, 2026 | 1.63 | 1.69 | 1.56 | 1.61 | 1.61 | 15,181,896 |
| Feb 10, 2026 | 1.61 | 1.64 | 1.58 | 1.62 | 1.62 | 11,746,520 |
| Feb 9, 2026 | 1.53 | 1.63 | 1.51 | 1.61 | 1.61 | 15,388,663 |
| Feb 6, 2026 | 1.48 | 1.57 | 1.46 | 1.53 | 1.53 | 17,924,265 |
| Feb 5, 2026 | 1.46 | 1.52 | 1.45 | 1.46 | 1.46 | 15,505,185 |
| Feb 4, 2026 | 1.50 | 1.53 | 1.46 | 1.47 | 1.47 | 12,028,982 |
| Feb 3, 2026 | 1.53 | 1.55 | 1.45 | 1.51 | 1.51 | 14,229,659 |
| Feb 2, 2026 | 1.35 | 1.58 | 1.34 | 1.54 | 1.54 | 27,161,513 |
| Jan 30, 2026 | 1.38 | 1.40 | 1.33 | 1.37 | 1.37 | 9,625,078 |
| Jan 29, 2026 | 1.34 | 1.39 | 1.29 | 1.37 | 1.37 | 22,237,656 |
| Jan 28, 2026 | 1.39 | 1.40 | 1.33 | 1.33 | 1.33 | 9,267,890 |
| Jan 27, 2026 | 1.35 | 1.39 | 1.35 | 1.38 | 1.38 | 5,804,078 |
| Jan 26, 2026 | 1.38 | 1.42 | 1.34 | 1.37 | 1.37 | 12,381,992 |
| Jan 23, 2026 | 1.41 | 1.44 | 1.35 | 1.38 | 1.38 | 11,938,454 |
| Jan 22, 2026 | 1.33 | 1.41 | 1.32 | 1.41 | 1.41 | 11,479,201 |
| Jan 21, 2026 | 1.30 | 1.35 | 1.29 | 1.34 | 1.34 | 7,593,131 |
| Jan 20, 2026 | 1.28 | 1.33 | 1.26 | 1.30 | 1.30 | 22,756,961 |
| Jan 16, 2026 | 1.32 | 1.37 | 1.30 | 1.31 | 1.31 | 13,268,564 |
| Jan 15, 2026 | 1.34 | 1.36 | 1.30 | 1.30 | 1.30 | 8,041,605 |
| Jan 14, 2026 | 1.31 | 1.35 | 1.28 | 1.35 | 1.35 | 10,273,111 |
| Jan 13, 2026 | 1.44 | 1.44 | 1.31 | 1.31 | 1.31 | 8,349,879 |
| Jan 12, 2026 | 1.35 | 1.48 | 1.31 | 1.43 | 1.43 | 21,634,105 |
| Jan 9, 2026 | 1.37 | 1.40 | 1.31 | 1.34 | 1.34 | 15,644,887 |
| Jan 8, 2026 | 1.35 | 1.40 | 1.32 | 1.37 | 1.37 | 8,779,722 |
| Jan 7, 2026 | 1.31 | 1.40 | 1.31 | 1.37 | 1.37 | 7,697,775 |
| Jan 6, 2026 | 1.32 | 1.34 | 1.30 | 1.32 | 1.32 | 5,451,334 |
| Jan 5, 2026 | 1.32 | 1.34 | 1.30 | 1.32 | 1.32 | 3,475,186 |
| Jan 2, 2026 | 1.33 | 1.36 | 1.30 | 1.32 | 1.32 | 5,655,230 |
| Dec 31, 2025 | 1.33 | 1.36 | 1.31 | 1.32 | 1.32 | 5,342,697 |
| Dec 30, 2025 | 1.35 | 1.38 | 1.33 | 1.34 | 1.34 | 4,050,645 |
| Dec 29, 2025 | 1.35 | 1.39 | 1.33 | 1.37 | 1.37 | 4,593,756 |
| Dec 26, 2025 | 1.38 | 1.40 | 1.36 | 1.37 | 1.37 | 3,511,541 |
| Dec 24, 2025 | 1.32 | 1.40 | 1.32 | 1.40 | 1.40 | 2,579,715 |
| Dec 23, 2025 | 1.33 | 1.34 | 1.30 | 1.33 | 1.33 | 5,649,414 |
| Dec 22, 2025 | 1.31 | 1.37 | 1.30 | 1.35 | 1.35 | 4,832,828 |
| Dec 19, 2025 | 1.36 | 1.36 | 1.31 | 1.33 | 1.33 | 11,810,836 |
| Dec 18, 2025 | 1.40 | 1.43 | 1.33 | 1.34 | 1.34 | 5,500,543 |
| Dec 17, 2025 | 1.35 | 1.45 | 1.34 | 1.40 | 1.40 | 12,396,270 |
| Dec 16, 2025 | 1.32 | 1.38 | 1.30 | 1.34 | 1.34 | 7,603,133 |
| Dec 15, 2025 | 1.35 | 1.38 | 1.33 | 1.33 | 1.33 | 8,515,693 |
| Dec 12, 2025 | 1.38 | 1.39 | 1.31 | 1.36 | 1.36 | 10,468,101 |
| Dec 11, 2025 | 1.27 | 1.42 | 1.26 | 1.39 | 1.39 | 16,304,017 |
| Dec 10, 2025 | 1.25 | 1.30 | 1.21 | 1.28 | 1.28 | 6,683,165 |
| Dec 9, 2025 | 1.26 | 1.27 | 1.23 | 1.23 | 1.23 | 4,299,425 |
| Dec 8, 2025 | 1.33 | 1.37 | 1.26 | 1.27 | 1.27 | 6,721,750 |
| Dec 5, 2025 | 1.27 | 1.32 | 1.26 | 1.31 | 1.31 | 4,671,414 |
| Dec 4, 2025 | 1.26 | 1.28 | 1.25 | 1.27 | 1.27 | 3,614,237 |
| Dec 3, 2025 | 1.23 | 1.28 | 1.23 | 1.27 | 1.27 | 7,663,733 |
| Dec 2, 2025 | 1.19 | 1.24 | 1.18 | 1.23 | 1.23 | 6,608,555 |
| Dec 1, 2025 | 1.15 | 1.20 | 1.15 | 1.19 | 1.19 | 6,433,954 |
| Nov 28, 2025 | 1.20 | 1.21 | 1.17 | 1.18 | 1.18 | 4,207,390 |
| Nov 26, 2025 | 1.14 | 1.21 | 1.14 | 1.19 | 1.19 | 6,243,479 |
| Nov 25, 2025 | 1.16 | 1.17 | 1.13 | 1.16 | 1.16 | 6,240,335 |
| Nov 24, 2025 | 1.12 | 1.16 | 1.11 | 1.16 | 1.16 | 7,017,768 |
| Nov 21, 2025 | 1.08 | 1.13 | 1.08 | 1.12 | 1.12 | 7,307,677 |
| Nov 20, 2025 | 1.11 | 1.13 | 1.07 | 1.10 | 1.10 | 12,198,162 |
| Nov 19, 2025 | 1.11 | 1.12 | 1.05 | 1.08 | 1.08 | 7,983,407 |
| Nov 18, 2025 | 1.12 | 1.14 | 1.08 | 1.11 | 1.11 | 4,847,071 |
| Nov 17, 2025 | 1.12 | 1.15 | 1.09 | 1.13 | 1.13 | 7,480,170 |
| Nov 14, 2025 | 1.14 | 1.17 | 1.10 | 1.12 | 1.12 | 8,035,255 |
| Nov 13, 2025 | 1.24 | 1.25 | 1.15 | 1.15 | 1.15 | 7,533,222 |
| Nov 12, 2025 | 1.25 | 1.28 | 1.23 | 1.24 | 1.24 | 6,462,828 |
| Nov 11, 2025 | 1.16 | 1.26 | 1.15 | 1.25 | 1.25 | 12,375,200 |
| Nov 10, 2025 | 1.07 | 1.17 | 1.07 | 1.16 | 1.16 | 16,683,987 |
| Nov 7, 2025 | 1.07 | 1.09 | 1.04 | 1.07 | 1.07 | 12,141,822 |
| Nov 6, 2025 | 1.07 | 1.11 | 1.05 | 1.08 | 1.08 | 8,283,491 |
| Nov 5, 2025 | 1.10 | 1.14 | 1.04 | 1.09 | 1.09 | 16,738,730 |
| Nov 4, 2025 | 1.18 | 1.22 | 1.14 | 1.15 | 1.15 | 13,369,824 |
| Nov 3, 2025 | 1.26 | 1.29 | 1.20 | 1.20 | 1.20 | 10,294,219 |
| Oct 31, 2025 | 1.23 | 1.26 | 1.22 | 1.26 | 1.26 | 5,292,838 |
| Oct 30, 2025 | 1.23 | 1.28 | 1.22 | 1.24 | 1.24 | 3,644,921 |
| Oct 29, 2025 | 1.30 | 1.30 | 1.22 | 1.23 | 1.23 | 5,014,783 |
| Oct 28, 2025 | 1.27 | 1.28 | 1.24 | 1.28 | 1.28 | 4,787,448 |
| Oct 27, 2025 | 1.26 | 1.28 | 1.24 | 1.28 | 1.28 | 5,450,587 |
| Oct 24, 2025 | 1.25 | 1.26 | 1.21 | 1.24 | 1.24 | 11,634,899 |
| Oct 23, 2025 | 1.24 | 1.25 | 1.21 | 1.22 | 1.22 | 3,326,267 |
| Oct 22, 2025 | 1.27 | 1.28 | 1.22 | 1.24 | 1.24 | 6,509,643 |
| Oct 21, 2025 | 1.28 | 1.31 | 1.25 | 1.27 | 1.27 | 7,500,312 |
| Oct 20, 2025 | 1.21 | 1.28 | 1.21 | 1.27 | 1.27 | 6,468,695 |
| Oct 17, 2025 | 1.22 | 1.24 | 1.19 | 1.20 | 1.20 | 5,249,189 |
| Oct 16, 2025 | 1.29 | 1.29 | 1.23 | 1.23 | 1.23 | 8,991,326 |
| Oct 15, 2025 | 1.27 | 1.31 | 1.25 | 1.28 | 1.28 | 10,999,146 |
| Oct 14, 2025 | 1.27 | 1.28 | 1.21 | 1.24 | 1.24 | 9,331,788 |
| Oct 13, 2025 | 1.33 | 1.34 | 1.26 | 1.27 | 1.27 | 12,084,308 |
| Oct 10, 2025 | 1.41 | 1.45 | 1.30 | 1.31 | 1.31 | 9,726,326 |
| Oct 9, 2025 | 1.39 | 1.44 | 1.38 | 1.39 | 1.39 | 7,830,460 |
| Oct 8, 2025 | 1.31 | 1.39 | 1.28 | 1.38 | 1.38 | 7,653,773 |
| Oct 7, 2025 | 1.30 | 1.31 | 1.26 | 1.29 | 1.29 | 4,610,669 |
| Oct 6, 2025 | 1.35 | 1.36 | 1.27 | 1.28 | 1.28 | 8,908,708 |
| Oct 3, 2025 | 1.40 | 1.48 | 1.34 | 1.35 | 1.35 | 11,070,523 |
| Oct 2, 2025 | 1.42 | 1.43 | 1.36 | 1.38 | 1.38 | 4,152,553 |
| Oct 1, 2025 | 1.35 | 1.44 | 1.35 | 1.41 | 1.41 | 5,379,831 |
| Sep 30, 2025 | 1.31 | 1.39 | 1.30 | 1.37 | 1.37 | 7,220,324 |
| Sep 29, 2025 | 1.31 | 1.34 | 1.29 | 1.31 | 1.31 | 3,795,206 |
| Sep 26, 2025 | 1.28 | 1.30 | 1.27 | 1.29 | 1.29 | 5,412,504 |
| Sep 25, 2025 | 1.35 | 1.36 | 1.27 | 1.27 | 1.27 | 5,546,270 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at GERN, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|